The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Open accessAbstract
BACKGROUND: A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy. METHODS: We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival. RESULTS: With a minimum of 2 years of follow-up (> or =3 years for 69% of patients), significantly more patients survived in the TPF group than in the PF group (hazard ratio for death, 0.70; P=0.006). Estimates of overall survival at 3 years were 62% in the TPF group and 48% in the PF group; the median overall survival was 71 months and 30 months, respectively (P=0.006). There was better locoregional control in the TPF group than in the PF group (P=0.04), but the incidence of distant metastases in the two groups did not differ significantly (P=0.14). Rates of neutropenia and febrile neutropenia were higher in the TPF group; chemotherapy was more frequently delayed because of hematologic adverse events in the PF group. CONCLUSIONS: Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy. (ClinicalTrials.gov number, NCT00273546 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationCooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Self-citationBernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,174
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
American Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
Lefebvre, J.-L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., & Sahmoud, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.890 · Cited by 1,334
Cited by
Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,067
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Chow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.12.017 · Cited by 1,174
Sun, Y., Li, W.-F., Chen, N.-Y., Zhang, N., Hu, G.-Q., Xie, F.-Y., Sun, Y., Chen, X.-Z., Li, J.-G., Zhu, X.-D., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30410-7 · Cited by 950
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905287 · Cited by 927
Recent Advances in Head and Neck Cancer
Haddad, R. I., & Shin, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707975 · Cited by 916
Self-citationMachiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., & Gregoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 916
Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I., & Saba, N. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01550-6 · Cited by 847
Self-citationThe changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Haddad, R., O'Neill, A., Rabinowits, G., Tishler, R., Khuri, F., Adkins, D., Clark, J., Sarlis, N., Lorch, J., Beitler, J. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70011-1 · Cited by 750
Self-citationHead and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.489 · Cited by 739
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Steuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Grégoire, V., Lefebvre, J.-L., Licitra, L., & Felip, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq185 · Cited by 628
Blanchard, P., Baujat, B., Holostenco, V., Bourredjem, A., Baey, C., Bourhis, J., & Pignon, J.-P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.036 · Cited by 621
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0026 · Cited by 614
Self-citationPointreau, Y., Garaud, P., Chapet, S., Sire, C., Tuchais, C., Tortochaux, J., Faivre, S., Guerrif, S., Alfonsi, M., & Calais, G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp007 · Cited by 577
Cohen, E. E. W., Karrison, T. G., Kocherginsky, M., Mueller, J., Egan, R., Huang, C. H., Brockstein, B. E., Agulnik, M. B., Mittal, B. B., Yunus, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.6309 · Cited by 571
Self-citationHui, E. P., Ma, B. B., Leung, S. F., King, A. D., Mo, F., Kam, M. K., Yu, B. K., Chiu, S. K., Kwan, W. H., Ho, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1545 · Cited by 523
Lorch, J. H., Goloubeva, O., Haddad, R. I., Cullen, K., Sarlis, N., Tishler, R., Tan, M., Fasciano, J., Sammartino, D. E., & Posner, M. R. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70279-5 · Cited by 448
Self-citationPredictors of Competing Mortality in Advanced Head and Neck Cancer
Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9288 · Cited by 433
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Self-citationZhong, L.-P., Zhang, C.-P., Ren, G.-X., Guo, W., William, W. N., Sun, J., Zhu, H.-G., Tu, W.-Y., Li, J., Cai, Y.-L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8820 · Cited by 394
Optimal treatment for recurrent/metastatic head and neck cancer
Vermorken, J. B., & Specenier, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq453 · Cited by 383
Elting, L. S., Keefe, D. M., Sonis, S. T., Garden, A. S., Spijkervet, F. K. L., Barasch, A., Tishler, R. B., Canty, T. P., Kudrimoti, M. K., Vera‐Llonch, M., et al. (2008) · Cancer · doi:10.1002/cncr.23898 · Cited by 373
Self-citationKeck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
Forastiere, A. A., Ismaila, N., Lewin, J. S., Nathan, C. A., Adelstein, D. J., Eisbruch, A., Fass, G., Fisher, S. G., Laurie, S. A., Le, Q.-T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7385 · Cited by 364
The molecular pathogenesis of head and neck squamous cell carcinoma
Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 363
Hitt, R., Grau, J. J., López-Pousa, A., Berrocal, A., García-Girón, C., Irigoyen, A., Sastre, J., Martínez-Trufero, J., Brandariz Castelo, J. A., Verger, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt461 · Cited by 353
Current trends in initial management of laryngeal cancer: the declining use of open surgery
Silver, C. E., Beitler, J. J., Shaha, A. R., Rinaldo, A., & Ferlito, A. (2009) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-009-1028-2 · Cited by 345
Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery
Takes, R. P., Strojan, P., Silver, C. E., Bradley, P. J., Haigentz, M., Wolf, G. T., Shaha, A. R., Hartl, D. M., Olofsson, J., Langendijk, J. A., et al. (2012) · Head & Neck · doi:10.1002/hed.21613 · Cited by 312
Blanchard, P., Bourhis, J., Lacas, B., Posner, M. R., Vermorken, J. B., Hernandez, J. J. C., Bourredjem, A., Calais, G., Paccagnella, A., Hitt, R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7802 · Cited by 300
Self-citationSettle, K., Posner, M. R., Schumaker, L. M., Tan, M., Suntharalingam, M., Goloubeva, O., Strome, S. E., Haddad, R. I., Patel, S. S., Cambell, E. V., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0149 · Cited by 296
Self-citationLefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn460 · Cited by 285
Head and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0142 · Cited by 283
Self-citationHead and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden
Hashim, D., Genden, E., Posner, M., Hashibe, M., & Boffetta, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz084 · Cited by 265
Self-citationAng, K. K., & Sturgis, E. M. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.004 · Cited by 260
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Head and neck cancer: An evolving treatment paradigm
Cognetti, D. M., Weber, R. S., & Lai, S. Y. (2008) · Cancer · doi:10.1002/cncr.23654 · Cited by 253
Kies, M. S., Holsinger, F. C., Lee, J. J., William, W. N., Glisson, B. S., Lin, H. Y., Lewin, J. S., Ginsberg, L. E., Gillaspy, K. A., Massarelli, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0425 · Cited by 253
Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105171 · Cited by 20
“The response rates seen in this trial are numerically less compared to previous induction chemotherapy trials.[8, 9, 34] Patients enrolled on TAX324 received induction chemotherapy followed by definitive concurrent chemoradiation – a paradigm similar to this trial.”
BackgroundResultTomkiewicz, C., Hans, S., Mucchielli, M. H., Agier, N., Delacroix, H., Marisa, L., Brasnu, D., Aggerbeck, L. P., Badoual, C., Barouki, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047170 · Cited by 10
Metadata
- Authors
- Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., Murphy, B. A., Raez, L. E., Cohen, R. B., Spaulding, M., Tishler, R. B., Roth, B., Viroglio, R. D. C., Venkatesan, V., Romanov, I., Agarwala, S., Harter, K. W., Dugan, M., Cmelak, A., Markoe, A. M., Read, P. W., Steinbrenner, L., Colevas, A. D., Norris, C. M., & Haddad, R. I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-25
- Volume
- 357
- Issue
- 17
- Pages
- 1705-1715
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141592118
- Cited by
- 1,705
- References
- 18
- FWCI
- 97.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.